⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
11,433
Total Claims
$5.8M
Drug Cost
1,190
Beneficiaries
$4,841
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+23%
Cost per patient vs peers
$4,841 vs $3,933 avg
+19%
Brand preference vs peers
60.8% vs 51.2% avg
Brand vs Generic
39% generic
Brand: 6,690 claims · $5.5M
Generic: 4,306 claims · $152K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 897 | $992K |
| Dulaglutide | 544 | $642K |
| Dapaglifloz Propaned/Metformin | 494 | $417K |
| Exenatide Microspheres | 225 | $276K |
| Dapagliflozin Propanediol | 287 | $245K |
| Sitagliptin Phos/Metformin Hcl | 274 | $233K |
| Sitagliptin Phosphate | 212 | $210K |
| Empagliflozin/Metformin Hcl | 228 | $195K |
| Insulin Glargine,hum.Rec.Anlog | 231 | $187K |
| Insulin Regular, Human | 57 | $186K |
| Insulin Lispro-Aabc | 205 | $152K |
| Empagliflozin | 146 | $149K |
| Semaglutide | 87 | $120K |
| Levothyroxine Sodium | 1,027 | $117K |
| Insulin Lispro | 115 | $95K |
Prescribing Profile
Patient Profile
75
Avg Age
64%
Female
2.15
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About